NCT02698657View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 23, 2016

Primary Completion Date

September 7, 2017

Study Completion Date

September 7, 2017

Conditions
Rheumatoid Arthritis (RA)
Interventions
DRUG

ASP5094

Intravenous (IV)

DRUG

Placebo

Intravenous (IV)

Trial Locations (13)

16635

Site US10003, Duncansville

32216

Site US10004, Jacksonville

33014

Site US10009, Miami Lakes

36207

Site US10002, Anniston

38119

Site US10010, Memphis

75231

Site US10001, Dallas

32713-1818

Site US10008, DeBary

82-300

Site PL48009, Elblag

31-637

Site PL48011, Krakow

91-347

Site PL48006, Lodz

Unknown

Site PL48007, Stalowa Wola

00-660

Site PL48003, Warsaw

50-556

Site PL48008, Wroclaw

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02698657 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate | Biotech Hunter | Biotech Hunter